FOLFIRI方案二线治疗晚期大肠癌临床疗效观察

目的观察FOLFIRI方案二线治疗晚期大肠癌的临床疗效和不良反应。方法病理确诊的44例晚期大肠癌患者接受FOLFIRI方案化疗：伊立替康（CPT．11）150nlg／m^2，静脉滴注，第1天；亚叶酸钙（CF）200mg／m^2，静脉滴注2h，第1、2天；5-氟尿嘧啶（5-Fu）400mg／／112，静脉注射，第1、2天后予5-Fu600mg／m。持续静脉滴注22h，第1、2天；每2周重复，化疗2次为1个周期。治疗4～6个周期后按实体瘤疗效评定标准评价疗效及不良反应。结果全组病例均可评价疗效，其中完全缓解2例，部分缓解16例，有效率为40．9％；中位生存期11．3个月，中位疾病进展时间6．5个月。主要的不良反应为乙酰胆碱能综合征和迟发性腹泻及骨髓抑制。结论FOLFIRI方案作为二线方案治疗晚期大肠癌疗效肯定，可使大部分患者临床受益，不良反应可以耐受，值得临床进一步试用、研究。

Clinical study of irinotecan combined with 5-Fu/CF in the treatment of patients with advanced colorectal cancer

Objective To evaluate the anti-tumor activity and toxicity of FOLFIRI regimen in the treatment of patients with advanced colorectal cancer. Methods 22 patients with advanced colorectal cancer used Irinotecan combined with 5-Fu/CF regimen to chemotherapy. Regimen: CPT-11 150 mg/m2 iv drip d1, CF 200 mg/m2 iv drip 2 h d1, 2; 5-Fu 400 mg/m2 iv drip d1, 2; 5-Fu 600 mg/m2 iv drip 22 h d1, 2. It is repeated every 2 weeks, two times a course. Efficiency and toxicity was evaluated after 4-6 cycles. Results Forty four patients were evaluated the efficiency. Two patients achieved CR, 16 PR, response rate was 40.9 %; MST was 11.3 months. TTP was 6.5 months. The main toxicity was cholinergic syndrome and delayed diarrhea,myelosuppression. There were no deaths during treatment. Conclusion The effectiveness of FOLFIRI regimen was higher and side effects was minor in advanced colorectal cancer. It should be further used and studied.